{"sources":[{"label":"Lilly FAQ","url":"https://www.lilly.com/news/stories/what-to-know-about-retatrutide","use":"Investigational status and mechanism"},{"label":"Lilly Phase 3 update","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average","use":"Recent trial topline and adverse-event reporting"},{"label":"NEJM phase 2 study","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","use":"Peer-reviewed background and common adverse events"},{"label":"ClinicalTrials.gov","url":"https://clinicaltrials.gov/study/NCT05882045","use":"Active trial context"},{"label":"FDA GLP-1 safety note","url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","use":"Caution around unapproved GLP-1 products"}]}